Breckenridge Pharmaceutical Inc. and partner Natco Pharma Limited are in pole position to be among the first US generic entrants for Amgen’s Kyprolis (carfilzomib) after Breckenridge received US Food and Drug Administration approval for its abbreviated new drug application.
The Indian firm noted that its partner had received final approval for 10mg and 60mg strengths of the product and...



